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SUMMARY
We present the case of a 43-year-old woman who
underwent total thyroidectomy with bilateral
lymphadenectomy for a papillary thyroid carcinoma
(PTC), solid variant (T4bN1bMx), with V600E BRAF
mutation. After ablative therapy, she presented
undetectable thyroglobulin (Tg) but progressively
increasing anti-Tg antibodies (TgAbs). During follow-up,
nodal, lung and brain metastases were identiﬁed. She
was submitted to surgical excision of lung lesions,
radiosurgery of brain metastases and ﬁve radioiodine
treatments. The latest brain MRI showed no lesions,
pulmonary CT showed stable micronodules and there
was progressive reduction in TgAbs. This is a peculiar
case of a PTC with lung and brain metastatic lesions
detected through TgAbs. Initial histological and
molecular study suggested a more aggressive clinical
behaviour, which was eventually conﬁrmed. Although
PTC brain metastases are extremely rare and present
poor prognosis, our patient presented a good response
to treatment and longer survival than usually reported
for similar cases.
BACKGROUND
Papillary thyroid carcinoma (PTC) is the most
common thyroid carcinoma, representing almost
85% of newly diagnosed cases.1 PTC has a rela-
tively benign course, with a 10-year survival rate of
90–95%.2 In adults, the frequency of nodal metas-
tasis may approach 90%, and is minuscule in half
the cases, without repercussion on patient progno-
sis.3 4 Only 10–15% of patients with differentiated
thyroid carcinoma develop distant metastasis, with
lungs and bones as the most frequently involved
organs.5 6 Brain metastasis occurs only in 0.1–5%
of cases.7 These lesions can be either totally silent
or very symptomatic and life-threatening. When
present, they can cause a signiﬁcant reduction in
survival. The median overall survival reported in a
previous series after brain metastasis diagnosis is
9.4 months.8–18
We report a peculiar case of a young woman
with PTC. This patient not only had positive thyro-
globulin autoantibodies (TgAbs), used as a marker
of clinical evolution, but also developed brain
metastasis. After being submitted to an aggressive
multimodal treatment approach, she presented a
signiﬁcantly longer survival than that usually
described for similar situations.
CASE PRESENTATION
We report a case of a 43-year-old woman with a
history of PTC (pT4N1bMx) submitted to total
thyroidectomy with bilateral lymphadenectomy fol-
lowed by radioactive iodine (RAI) remnant ablating
after levothyroxine withdrawal (April 2000). The
histological study conﬁrmed a PTC, solid variant,
devoid of capsule and with extra-thyroid tissue
invasion; massive metastases were found in 9 left
and 13 right cervical lymph nodes. The molecular
study of the tumour revealed the presence of the
V600E BRAF mutation with neither telomerase
reverse transcriptase (TERT) nor NRAS alterations.
The patient received 170mCi of RAI (131I) for
ablation; a post-therapy whole body scan (WBS)
showed strong cervical uptake compatible with
thyroid remnants, together with a lesion on the
suprasternal notch area and diffuse bilateral pul-
monary uptake. Subsequently, the patient was
maintained under suppressive therapy with
levothyroxine.
After initial treatment, her thyroglobulin (Tg)
levels progressively reduced to values <1 ng/mL
after 14 months, but her TgAbs never decreased
below the positive cut-off level, and after an initial
ﬂuctuation period, gradually increased over time,
reaching values of 4349 UI/mL (ﬁgure 1). At this
time, neck ultrasound revealed no signiﬁcant altera-
tions, but RAI WBS showed suprasternal, laterocer-
vical and pulmonary uptake. Chest and abdomen
CT scans revealed bilateral multiple small pulmon-
ary lesions <8 mm in size. The patient received
two other RAI treatments (December 2000 and
July 2001, respectively), following levothyroxine
withdrawal, with a total dose of 147mCi and
162mCi of 131I, respectively. Over the next 8 years,
she presented good general performance and con-
tinual echographic surveillance revealed no new
lesions. Analytical follow-up showed stable TgAbs
(between 2000 and 3000 UI/mL), with undetect-
able Tg levels ( ﬁgure 1).
Later, there was an exponential increase of
TgAbs, which reached values of 17 781 UI/mL in
February 2009 (ﬁgure 1), and she was submitted to
a fourth course of RAI therapy with 135mCi of
Figure 1 Thyroglobulin (Tg) and Tg antibody (TgAb)
evolution during follow-up.
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131I, following levothyroxine withdrawal, which showed strong
bilateral pulmonary uptake that was more pronounced in infer-
ior lobes at post-treatment scintigraphy combined with single
photon emission CT (SPECT/CT) (ﬁgure 2). The patient per-
formed a brain, neck and chest CT (December 2009), which
not only conﬁrmed the multiple known pulmonary nodules but
also showed a brain lesion, characterised by brain MRI as a
lesion of the right frontoparietal lobe, 10 mm in diameter. She
was submitted to a surgical excision of pulmonary lesions
( January 2010), with histological study conﬁrming them as PTC
metastases, and to a ﬁfth RAI treatment with 190mCi of 131I
(April 2010); the post-treatment WBS showed strong pulmonary
uptake and also uptake in frontoparietal and cerebellar areas of
the brain (ﬁgure 3). These lesions were conﬁrmed through brain
MRI (ﬁgure 4). At that time, the TgAbs reached 18 483 UI/mL.
The patient was submitted to gamma knife radiosurgery (GKR)
in June 2010, 18 Gy, in frontoparietal and cerebellar lesions.
She received oral dexamethasone 2 mg four times a day, begin-
ning the day prior to GKR and lasting for 3 months after treat-
ment. In June 2011, after an initial slight increase of the
cerebral lesion documented by MRI, a sixth course of RAI
therapy was performed with 238mCi of 131I; the WBS showed
Figure 2 Post-treatment scintigraphy
(with single photon emission CT) after
administration of 135mCi of 131I
(February 2009) showing a strong
bilateral pulmonary uptake more
pronounced in inferior lobes.
Figure 3 Post-treatment scintigraphy
(with single photon emission CT) after
administration of 190mCi of 131I (April
2010) showing strong pulmonary
uptake and an uptake in frontoparietal
and cerebellar areas of the brain.
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no uptake in cerebral lesion and a less intense uptake in bilateral
pulmonary small nodules. In December 2011, the patient was
submitted to the last cycle of RAI therapy with 213mCi of 131I;
the WBS showed remnant pulmonary bilateral small lesions.
The last two courses of RAI therapy were performed under
recombinant human thyroid-stimulating hormone (TSH) stimu-
lation. At this point, the patient had been submitted to a total
cumulative dose of 1255mCi of 131I. Just before the last round
of RAI therapy (December/2011), we performed positron emis-
sion tomography (PET/CT) with 124I, which showed a slight
uptake in pulmonary lesions, and an 18F-ﬂudeoxyglucose PET/
CT, which showed no pathological uptake (ﬁgure 5). Serial
brain MRI performed over time showed reduction of brain
metastases (ﬁgure 4), punctiform in the latest evaluations, and
there was a progressive reduction of TgAbs (ﬁgure 1).
OUTCOME AND FOLLOW-UP
The patient has now been followed for 15 years, presenting
stable cerebral and pulmonary lesions, absence of new structural
lesions, progressively decreasing TgAbs levels and no signiﬁcant
alterations in biochemical tests of liver and kidney function or
blood count. In addition, she has been clinically free of
intracranial hypertension and demonstrates good performance
in her daily activities, more than 60 months after the diagnosis
of brain metastases.
DISCUSSION
We report a situation of a young woman with an aggressive
histological subtype of PTC diagnosed in an advanced stage,
with the presence of one mutation conferring a worse progno-
sis, and the other mutations analysed being negative. BRAF
V600E mutation has been associated with lower sodium-iodide
symporter (NIS) expression and radioiodine-resistant metastatic
lesions; this is in agreement with the evolution of the patient
being presented, who was submitted to seven courses of radioio-
dine therapy with a large cumulative dose to control the
disease.19 20 After initial treatment, her follow-up was particu-
larly interesting as the marker of persistent or recurrent disease
was the titre of TgAbs. These antibodies are identiﬁed in about
20–25% of patients with differentiated thyroid carcinoma.21
When present, they interfere with the measurement of Tg, the
primary biochemical marker used for thyroid carcinoma surveil-
lance, which precludes Tg use for patient monitoring. There has
been growing evidence that TgAbs levels themselves may serve
Figure 4 Brain MRI showing
frontoparietal brain lesion before (A)
and after (B) gamma knife
radiosurgery treatment.
Figure 5 (A) Post-treatment scintigraphy (with single photon emission CT) after administration of 213mCi of 131I (December 2011) showing only
remaining pulmonary bilateral small lesions; (B) positron emission tomography CT (PET/CT) with 124I showing a slight uptake in pulmonary lesions
(December 2011); (C) 18F-ﬂudeoxyglucose PET/CT showing no abnormal uptake.
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as a surrogate biochemical marker of disease persistence and
response to therapy. However, the timing of testing and the dur-
ation to the maximal response seems to differ from Tg. For
instance, there may be an initial transient rise in TgAbs after
RAI therapy.22 Also, it has been shown that the eventual dis-
appearance of TgAbs takes approximately 2–3 years on average,
with some patients having a very slow decrease of TgAbs levels
that can take much longer than 3 years to resolve.22–24 We and
others advocate that the best approach for patients with persist-
ently detectable (or even rising) TgAbs is to perform a prompt
evaluation;25 this was carried out in the case we report and led
to the diagnosis of distant metastases. The approach should be
different for patients with rising TG, in whom the performance
of a WBS is indicated. However, we must take into account that
neither the probability of ﬁnding thyroid cancer in this setting
nor the best method for disease localisation has been ﬁrmly
established. In our patient, the ultrasound evaluations were per-
sistently normal but the exponential rise of TgAbs led to the
performance of WBS and CT, which conﬁrmed the presence of
secondary lesions.
Compared to other locations, brain metastases from PTC are
extremely rare and are often associated with poor prognosis.7
The majority of brain metastases involve brain parenchyma, as
in our case, probably due to the blood–meningeal barrier, and
blood distribution within the brain and central nervous
system.26 As shown in previous case reports,27 28 patients with
brain metastases usually showed other secondary localisations
such as in the lungs, bones or liver, which may be primary meta-
static sites potentially through haematogenic dissemination.
Brain metastases can be unique or numerous, clinically silent or
very symptomatic, leading to intracranial high pressure and
strong headaches, vomiting or focal neurological complica-
tions.29 Fortunately, in our patient, these lesions were always
completely silent. According to different authors, the reported
median survival of PTC brain metastases varies from 4 to 33
months.8–18 Predictive factors of survival seem to be advanced
age, male gender, extra-thyroidal invasion and metastases at
presentation, histological grade and incomplete resection of
primary thyroid cancer.30 In our patient, the early detection of
recurrent disease inferred by indirect markers (TgAbs) led to a
more aggressive approach, which probably contributed to the
unusually good outcome.
Several treatment modalities have been used in a limited
number of patients with intracranial metastatic PTC, including
surgical resection, external beam radiation, radiosurgery (includ-
ing GKR) and radioiodine therapy.16 To date, chemotherapy has
not been recommended in patients with brain metastases from
PTC.16 Surgical resection is only possible for accessible lesions,
and external beam radiation for cerebral metastases can also
cause complications such as cerebral oedema and trans-stentorial
herniations.31 Thus, in our patient, we chose to perform GKR.
The use of this technique has not been well deﬁned and only
scattered data have been reported.17 32 This approach has the
advantage of being minimally invasive and, in our case, it
improved tumour control. Some authors have also suggested
that the combination of GKR with RAI therapy, in comparison
to each modality alone, would improve tumour management.33
Once cerebral lesions in our patient showed radioiodine uptake,
she was also submitted to two additional RAI treatments. Given
the possibility that even small metastatic brain tissue growth can
cause signiﬁcant symptoms, we decided to avoid the prolonged
stimulation by TSH that occurs during thyroid hormone with-
drawal. Even without a formal indication, we decided to use
recombinant human TSH stimulation because we think it is the
most reasonable approach. Although guidelines for clinical prac-
tice cannot be derived from isolated reports, the authors think
that this case illustrates how different modes of follow-up and
treatment can be used to promote asymptomatic and prolonged
survival.
In conclusion, we present an atypical case of brain metastasis of
PTC in a young woman, whose follow-up was performed using
TgAbs levels. Pulmonary and brain metastases were surgically,
radiosurgically and radiometabolically treated, resulting in a longer
survival rate than those reported in similar cases. Early detection
and speciﬁc treatment may have been key factors to maintain the
patient’s quality of life, avoiding the development of complications
such as brain hypertension, and to prolong her survival.
Learning points
▸ Thyroglobulin antibody (TgAb) levels can be a surrogate
biochemical marker of papillary thyroid carcinoma (PTC)
persistence and response to therapy.
▸ Persistent or rising levels of TgAbs should lead to a prompt
evaluation similar to that in a patient with persistent or
rising Tg.
▸ The early detection and treatment of selected PTC brain
metastases with GKR and RAI can result in a long survival.
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